RxDoctor Payments Data

McKay Platt, MD

Urology · Provo, UTNPI 1336230085

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations.

$5,158in general payments, 2019–2025

Across 265 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • 180 Medical, Inc.$834
  • Endo Pharmaceuticals Inc.$725
  • AbbVie$720
  • Boston Scientific$401
  • Pfizer$326
  • Astellas Pharma US Inc$211
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$5,06998%
  • Education$892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,158 in reported general payments places this provider in the 60th percentile of 96 urology providers in Utah.

See all urology providers in Utah

Medicare billing

Part B allowed, 2024
$306,509
Medicare patients
500
Services billed
5,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron132$91,206
Tamsulosin Hcl542$5,271
Finasteride381$4,519
Solifenacin Succinate155$3,857
Potassium Citrate ErPotassium Citrate40$3,160
Abiraterone Acetate12$2,441
Testosterone Cypionate25$1,225
Bicalutamide42$968
Dutasteride15$620
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim76$600
Oxybutynin Chloride ErOxybutynin Chloride27$504
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen72$374
Tolterodine Tartrate12$351
Allopurinol16$309
Alfuzosin Hcl ErAlfuzosin Hcl13$276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$211$91,206132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 96 urology providers in Utah.

Other urology in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →